Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.

ABSTRACT:

Background

Transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) is often repeated until unTACEable progression (UTP) occurs. There is little data on the various reasons for stopping TACE and its consequences for subsequent treatment and survival.

Aim

To assess the impact of the various reasons of UTP on survival and consequences for subsequent treatments.

Methods

Consecutive HCC patients who underwent TACE between 2003 and 2016 were analyzed retrospectively for the reason of TACE discontinuation. UTP was defined according to the EASL guidelines, considering radiological pattern of progression, liver function and performance status (PS). Overall and post-progression survival (OS, PPS) for different reasons of TACE discontinuation

SUBMITTER: Labeur TA 

PROVIDER: S-EPMC6344387 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature